Anavex appoints leading Alzheimer's disease expert Dr. Mark Smith to scientific advisory board.
ATHENS, Feb. 10 /PRNewswire-FirstCall/ -- Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) today announced the appointment of Dr. Mark A. Smith, Ph.D., FRCPath, to its scientific advisory board. Dr. Smith is recognized as one of the world's most cited researchers in the fields of Alzheimer's disease, free radical biology...

Florida and California Represent Equivalent Areas of Opportunity in the Alzheimer's Disease Drug Market.
Florida's Alzheimer's Disease Population is Undertreated When Compared to California, According to a New Analytics Tool From Decision Resources WALTHAM, Mass., Jan. 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Florida and California...

Anavex scales up synthesis of ANAVEX 2-73 for Phase 1 Alzheimer's disease study.
ATHENS, Greece, Feb. 2 /PRNewswire-FirstCall/ -- Anavex Life Sciences Corp., ("ANAVEX") (OTCBB: AVXL) has signed an agreement with organic chemistry services provider Syntagon AB ("Syntagon") for the scale-up manufacturing of ANAVEX 2-73, its lead compound for the treatment of Alzheimer's disease. ANAVEX 2-73 is scheduled to commence Phase 1...

New Venture Funding for Alzheimer's Disease Drug Developer.
MADISON, Wis., Jan. 12 /PRNewswire/ -- Mithridion, Inc., a drug development company focusing on serious Central Nervous System disorders, including Alzheimer's disease (AD), announced today that it held an initial closing of $2.9 million in Series B Preferred Stock financing. The company will use the funds for the clinical...

Effect of physical activity on cognitive function for Alzheimer's disease.
Lautenschlager NT, Cox KL, Flicker L, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. Journal of the American Medical Association 2008;300(9):1027-1037. Aim Of This Study This study was undertaken to assess whether 24...

ChemDiv and Avineuro Extend Collaboration on Alzheimer's Disease and Schizophrenia.
SAN DIEGO, Nov. 21 /PRNewswire/ -- ChemDiv Inc. and Avineuro Pharmaceuticals Inc. have extended the term of their research and development collaboration including formulation, safety and early clinical development studies in areas of neurodegenerative and psychiatric disorders. R&D services will be provided by Chemical Diversity Research Institute, ChemDiv's research...

Alzheimer's disease: something's not right with mom ... and now Dad.
One family's moving struggle as their parents retreated further into the depths of Alzheimer's disease. It is a simple television remote. But it is making our family crazy. Cable TV has arrived at my parents' house, and with it has come a more complicated channel...

Lilly Gears Up to Begin Second Global Phase III Trial of Investigational Alzheimer's Disease Compound.
HEALTH AND BEAUTY CLOSE-UP-3 October 2008-Lilly Gears Up to Begin Second Global Phase III Trial of Investigational Alzheimer's Disease Compound(C)2008 - CloseUpMedia - newsdesk@closeupmedia.com Eli Lilly and Company announced that it will begin enrolling patients in a second Phase III study of LY450139, a gamma-secretase inhibitor being...

Blood test may identify Alzheimer's disease.
CHICAGO -- A simple blood test could soon allow clinicians--even primary care physicians--to diagnose Alzheimer's disease accurately if a final validation study succeeds as optimistic researchers hope. In an initial study of 88 patients, the test findings agreed with expert clinical diagnosis more than 90% of the...

This November Celebrate National Alzheimer's Disease Awareness Month.
AegisLiving is a Leading Caretaker for Those Struggling With the Disease REDMOND, Wash., Nov. 7 /PRNewswire/ -- The statistics are staggering when considering what an impact Alzheimer's disease has on many American lives. Already nearly five million people in this country alone have been diagnosed with the...